<?xml version="1.0" encoding="UTF-8"?>
<p id="p0675">Anti-NS1 has been shown to reduce virus replication in vivo, which has been proposed to be mediated by either antibodies/complement or cell-mediated cytotoxicity (
 <xref rid="bib14" ref-type="bibr">Amorim et al., 2012</xref>, 
 <xref rid="bib65" ref-type="bibr">Costa et al., 2006</xref>, 
 <xref rid="bib344" ref-type="bibr">Wu et al., 2003</xref>). NS1/anti-NS1 immune complexes can activate complement and have been proposed to drive complement consumption and promote vascular leak (
 <xref rid="bib23" ref-type="bibr">Avirutnan et al., 2006</xref>). Finally, anti-NS1 antibodies have been shown to cross-react with unknown epitopes on platelets and endothelium and have been proposed to drive dengue pathogenesis (
 <xref rid="bib204" ref-type="bibr">Lin et al., 2006</xref>). The ability of an antibody to neutralize a virus is thus related to its functional avidity for the whole virion.
</p>
